• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY:PFE)

    27.61 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EST, Feb 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pfizer

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
    The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it. 
    Via The Motley Fool
    News headline image
    Is 2026 the Year of Dividend Stocks? These 2 Income-Focused ETFs Have Been Soaring Past the S&P 500 ↗
    These funds both pay more than 3% and have been beating the market this year. 
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    CVS Health Navigates a Stormy 2026: Record Revenue Tempered by Medicare Advantage Costs and PBM Turmoil
    In a pivotal earnings report delivered on February 10, 2026, CVS Health (NYSE: CVS) showcased a complex narrative of financial resilience and operational headwinds. While the healthcare giant posted... 
    Via MarketMinute
    Topics Economy
    News headline image
    Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
    Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
    Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British... 
    Via Finterra
    Topics Artificial Intelligence Economy Fraud
    News headline image
    Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
    February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
    Via Finterra
    Topics Economy World Trade
    News headline image
    Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
    The stock has climbed in the triple digits over the past three years. 
    Via The Motley Fool
    News headline image
    5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call
    Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins.... 
    Via StockStory
    Topics Artificial Intelligence Earnings
    News headline image
    Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend? ↗
    The stock has been fairly stable over the past year. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗
    Which of the highest-yielding healthcare stocks are value traps or golden opportunities? 
    Via The Motley Fool
    News headline image
    AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
    In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a... 
    Via TokenRing AI
    Topics Artificial Intelligence
    News headline image
    Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal
    In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially.... 
    Via MarketMinute
    Topics Economy Government Immigration
    News headline image
    The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
    The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
    As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade... 
    Via Finterra
    Topics Economy Government Intellectual Property
    News headline image
    Broad-Based Prosperity: S&P 500 Defies Headwinds with 10.1% Growth as Tech Reclaims Its Crown
    The fourth-quarter earnings season of 2025 has reached a fever pitch, delivering a resounding message of resilience to Wall Street. As of February 6, 2026, the S&P 500 has reported an aggregate... 
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
    From Pfizer Inc.
    Via Business Wire
    News headline image
    Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most ↗
    Via MarketBeat
    News headline image
    Trade War 2.0: 25% Tariffs on Chips, Cars, and Medicine Reshape the Global Supply Chain
    The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of... 
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
    In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a... 
    Via MarketMinute
    Topics Earnings Economy
    News headline image
    Pfizer (PFE) Q4 2024 Earnings Call Transcript ↗
    Pfizer (PFE) Q4 2024 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Pfizer (PFE) Q3 2024 Earnings Call Transcript ↗
    Pfizer (PFE) Q3 2024 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Pfizer (PFE) Q2 2025 Earnings Call Transcript ↗
    Pfizer (PFE) Q2 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings World Trade
    News headline image
    Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
    The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes... 
    Via Stocktwits
    Topics Economy Government World Trade
    News headline image
    Men's Health Network Launches "My Cancer, My Plan" Podcast on World Cancer Day
    Via PRLog
    Topics Death
    News headline image
    The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)
    As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization... 
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
    Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
    Via The Motley Fool
    These S&P500 stocks are the most active in today's session ↗
    Via Chartmill
    News headline image
    Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
    Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board. 
    Via The Motley Fool
    AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗
    Via Chartmill
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.